342 related articles for article (PubMed ID: 33439272)
1. Generation and manipulation of human iPSC-derived platelets.
Sugimoto N; Eto K
Cell Mol Life Sci; 2021 Apr; 78(7):3385-3401. PubMed ID: 33439272
[TBL] [Abstract][Full Text] [Related]
2. [Ex vivo platelet production from induced pluripotent stem cells].
Sugimoto N; Eto K
Rinsho Ketsueki; 2018; 59(10):1905-1913. PubMed ID: 30305491
[TBL] [Abstract][Full Text] [Related]
3. Platelet production from induced pluripotent stem cells.
Sugimoto N; Eto K
J Thromb Haemost; 2017 Sep; 15(9):1717-1727. PubMed ID: 28752663
[TBL] [Abstract][Full Text] [Related]
4. Ex Vivo Manufacture of Megakaryocytes and Platelets from Stem Cells: Recent Advances Toward Transfusion in Humans.
Catelli LF; Saad STO
Stem Cells Dev; 2021 Apr; 30(7):351-362. PubMed ID: 33622080
[TBL] [Abstract][Full Text] [Related]
5. Generation and characterization of HLA-universal platelets derived from induced pluripotent stem cells.
Norbnop P; Ingrungruanglert P; Israsena N; Suphapeetiporn K; Shotelersuk V
Sci Rep; 2020 May; 10(1):8472. PubMed ID: 32439978
[TBL] [Abstract][Full Text] [Related]
6. [Clinical applications of iPS cell-derived platelets].
Sugimoto N; Eto K
Rinsho Ketsueki; 2022; 63(10):1430-1439. PubMed ID: 36351652
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo generation of platelet products from human iPS cells.
Nakamura S; Sugimoto N; Eto K
Inflamm Regen; 2020 Dec; 40(1):30. PubMed ID: 33292717
[TBL] [Abstract][Full Text] [Related]
8. Selective Inhibition of ADAM17 Efficiently Mediates Glycoprotein Ibα Retention During Ex Vivo Generation of Human Induced Pluripotent Stem Cell-Derived Platelets.
Hirata S; Murata T; Suzuki D; Nakamura S; Jono-Ohnishi R; Hirose H; Sawaguchi A; Nishimura S; Sugimoto N; Eto K
Stem Cells Transl Med; 2017 Mar; 6(3):720-730. PubMed ID: 28297575
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo manufacturing of platelets: beyond the first-in-human clinical trial using autologous iPSC-platelets.
Chen SJ; Sugimoto N; Eto K
Int J Hematol; 2023 Mar; 117(3):349-355. PubMed ID: 36574167
[TBL] [Abstract][Full Text] [Related]
10. Scalable generation of universal platelets from human induced pluripotent stem cells.
Feng Q; Shabrani N; Thon JN; Huo H; Thiel A; Machlus KR; Kim K; Brooks J; Li F; Luo C; Kimbrel EA; Wang J; Kim KS; Italiano J; Cho J; Lu SJ; Lanza R
Stem Cell Reports; 2014 Nov; 3(5):817-31. PubMed ID: 25418726
[TBL] [Abstract][Full Text] [Related]
11. Characterization of induced pluripotent stem cell-derived megakaryocyte lysates for potential regenerative applications.
Baigger A; Eicke D; Yuzefovych Y; Pogozhykh D; Blasczyk R; Figueiredo C
J Cell Mol Med; 2018 Sep; 22(9):4545-4549. PubMed ID: 29893509
[TBL] [Abstract][Full Text] [Related]
12. iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity.
Suzuki D; Flahou C; Yoshikawa N; Stirblyte I; Hayashi Y; Sawaguchi A; Akasaka M; Nakamura S; Higashi N; Xu H; Matsumoto T; Fujio K; Manz MG; Hotta A; Takizawa H; Eto K; Sugimoto N
Stem Cell Reports; 2020 Jan; 14(1):49-59. PubMed ID: 31883921
[TBL] [Abstract][Full Text] [Related]
13. [Novel platelet pharming using human induced pluripotent stem cells].
Flahou C; Sugimoto N; Eto K
Bull Acad Natl Med; 2020 Dec; 204(9):961-970. PubMed ID: 33012790
[TBL] [Abstract][Full Text] [Related]
14. Two differential flows in a bioreactor promoted platelet generation from human pluripotent stem cell-derived megakaryocytes.
Nakagawa Y; Nakamura S; Nakajima M; Endo H; Dohda T; Takayama N; Nakauchi H; Arai F; Fukuda T; Eto K
Exp Hematol; 2013 Aug; 41(8):742-8. PubMed ID: 23618622
[TBL] [Abstract][Full Text] [Related]
15. Isolation, Cryopreservation, and Characterization of iPSC-Derived Megakaryocytes.
Pogozhykh D; Blasczyk R; Figueiredo C
Methods Mol Biol; 2021; 2180():539-554. PubMed ID: 32797433
[TBL] [Abstract][Full Text] [Related]
16. Intersecting Worlds of Transfusion and Transplantation Medicine: An International Symposium Organized by the Canadian Blood Services Centre for Innovation.
Hodgkinson KM; Kiernan J; Shih AW; Solh Z; Sheffield WP; Pineault N
Transfus Med Rev; 2017 Jul; 31(3):183-192. PubMed ID: 28385575
[TBL] [Abstract][Full Text] [Related]
17. [Development of iPS cell-derived blood products and production guidelines].
Sugimoto N; Eto K
Rinsho Ketsueki; 2017; 58(10):2150-2159. PubMed ID: 28978860
[TBL] [Abstract][Full Text] [Related]
18. Production and nonclinical evaluation of an autologous iPSC-derived platelet product for the iPLAT1 clinical trial.
Sugimoto N; Nakamura S; Shimizu S; Shigemasa A; Kanda J; Matsuyama N; Tanaka M; Hayashi T; Fuchizaki A; Nogawa M; Watanabe N; Okamoto S; Handa M; Sawaguchi A; Momose D; Koh KR; Tani Y; Takaori-Kondo A; Eto K
Blood Adv; 2022 Dec; 6(23):6056-6069. PubMed ID: 36149941
[TBL] [Abstract][Full Text] [Related]
19. Improving Human Induced Pluripotent Stem Cell-Derived Megakaryocyte Differentiation and Platelet Production.
Krisch L; Brachtl G; Hochmann S; Andrade AC; Oeller M; Ebner-Peking P; Schallmoser K; Strunk D
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360992
[TBL] [Abstract][Full Text] [Related]
20. Turbulence Activates Platelet Biogenesis to Enable Clinical Scale Ex Vivo Production.
Ito Y; Nakamura S; Sugimoto N; Shigemori T; Kato Y; Ohno M; Sakuma S; Ito K; Kumon H; Hirose H; Okamoto H; Nogawa M; Iwasaki M; Kihara S; Fujio K; Matsumoto T; Higashi N; Hashimoto K; Sawaguchi A; Harimoto KI; Nakagawa M; Yamamoto T; Handa M; Watanabe N; Nishi E; Arai F; Nishimura S; Eto K
Cell; 2018 Jul; 174(3):636-648.e18. PubMed ID: 30017246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
